Opendata, web and dolomites

Olfactomics

Bringing Surgery to the 21st Century: Feasibility Verification of Real-time Tissue Analysis During Surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Olfactomics" data sheet

The following table provides information about the project.

Coordinator
OLFACTOMICS OY 

Organization address
address: AAKKULANKATU 4 C 9
city: TAMPERE
postcode: 33700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://olfactomics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OLFACTOMICS OY FI (TAMPERE) coordinator 50˙000.00

Map

 Project objective

Olfactomics is a Finnish university-based spinoff company developing a novel technology for surgical tissue assessment. The company has a breakthrough innovation on improving breast-conserving lumpectomies where a residual tumour continues to be an issue. Real-time tissue analysis allows the surgeon to remove a whole tumour in one operation and minimise the resection of healthy tissues. The patented technology (TRL 6) allows safer and more cost-effective cancer surgery and is scalable to most soft-tissue surgery. The unique device allows the surgeon to analyse the operated tissue in real-time during cancer surgery leading to optimal tissue removal. There is a global economy-justified need for real-time analysis in surgery. The Olfactomics device is fully aligned with current clinical workflow and instrumentation. It can be efficiently implemented to 835 000 breast surgeries every year, and it is scalable to multiple other areas. The commercialisation is targeting to 250 M€ revenue by 2027. The core team has the enthusiasm and knowledge needed for the commercialisation: team members are specialists in surgery, clinical medicine, medical technology, software, data analysis, financial sector and corporate law and have excellent connections in the international healthcare industry. The aim of this feasibility study is to analyse the feasibility from different perspectives and detail the business plan for the global commercialisation of the technology. The first commercial product will be a research device launched 2019. The scale-up to medical device and applications on several surgical areas will follow.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OLFACTOMICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OLFACTOMICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More